AAPL345.41+1.42 (+0.41%) ▲|ABBV282.81-1.91 (-0.67%) ▼|ABT100.83+0.32 (+0.32%) ▲|ACN243.65+3.39 (+1.41%) ▲|ADBE261.00+5.94 (+2.33%) ▲|AMAT385.01-23.93 (-5.85%) ▼|AMD520.57-32.15 (-5.82%) ▼|AMGN447.10+8.76 (+2.00%) ▲|AMT181.05+3.41 (+1.92%) ▲|AMZN253.55-8.83 (-3.36%) ▼|AVGO328.88-8.92 (-2.64%) ▼|AXP325.91+2.30 (+0.71%) ▲|BA190.70-1.58 (-0.82%) ▼|BAC51.04+0.26 (+0.51%) ▲|BKNG164.56+6.18 (+3.90%) ▲|BLK1,152.99+3.39 (+0.29%) ▲|BMY62.13+1.01 (+1.65%) ▲|BNY144.81-1.05 (-0.72%) ▼|BRK-B545.07+6.08 (+1.13%) ▲|C123.17-0.68 (-0.55%) ▼|CAT710.58-29.63 (-4.00%) ▼|CL96.06+2.66 (+2.85%) ▲|CMCSA23.08+1.00 (+4.51%) ▲|COF208.00+1.34 (+0.65%) ▲|COP144.42-1.26 (-0.86%) ▼|COST1,005.53+7.22 (+0.72%) ▲|CRM245.89+4.11 (+1.70%) ▲|CSCO104.85-2.41 (-2.25%) ▼|CVS93.47+0.69 (+0.74%) ▲|CVX225.32-1.47 (-0.65%) ▼|DE632.04-4.50 (-0.71%) ▼|DHR233.42-0.45 (-0.19%) ▼|DIS112.53+0.70 (+0.63%) ▲|DUK122.53+1.86 (+1.54%) ▲|EMR157.73-5.38 (-3.30%) ▼|FDX302.19+3.96 (+1.33%) ▲|GD346.65+1.94 (+0.56%) ▲|GE290.96-4.92 (-1.66%) ▼|GEV849.17-76.75 (-8.29%) ▼|GILD156.14+2.57 (+1.67%) ▲|GM77.98+1.87 (+2.46%) ▲|GOOG323.80-7.15 (-2.16%) ▼|GOOGL327.81-6.95 (-2.08%) ▼|GS899.02-5.71 (-0.63%) ▼|HD322.34+8.20 (+2.61%) ▲|HON213.10-1.64 (-0.76%) ▼|IBM243.58-7.88 (-3.13%) ▼|INTC88.10-4.86 (-5.23%) ▼|INTU347.07+11.46 (+3.41%) ▲|ISRG436.70+8.58 (+2.00%) ▲|JNJ263.16+5.38 (+2.09%) ▲|JPM335.97+0.78 (+0.23%) ▲|KO94.12+1.44 (+1.55%) ▲|LIN504.02+3.45 (+0.69%) ▲|LLY1,305.45+34.70 (+2.73%) ▲|LMT587.36+35.85 (+6.50%) ▲|LOW201.93+5.37 (+2.73%) ▲|LRCX238.04-22.77 (-8.73%) ▼|MA627.22+4.60 (+0.74%) ▲|MCD249.03+2.78 (+1.13%) ▲|MDLZ63.83+1.09 (+1.74%) ▲|MDT94.57+1.54 (+1.66%) ▲|META655.19-42.33 (-6.07%) ▼|MMM175.45+0.71 (+0.40%) ▲|MO74.82+0.99 (+1.34%) ▲|MRK153.13+3.25 (+2.17%) ▲|MS185.19-1.82 (-0.97%) ▼|MSFT524.76-8.20 (-1.54%) ▼|MU897.15-16.52 (-1.81%) ▼|NEE80.42+2.14 (+2.73%) ▲|NFLX66.40+1.36 (+2.09%) ▲|NKE37.75+0.22 (+0.57%) ▲|NOW155.48+2.36 (+1.54%) ▲|NVDA215.93-6.04 (-2.72%) ▼|ORCL127.11-2.03 (-1.57%) ▼|PEP136.89+2.19 (+1.63%) ▲|PFE30.26+0.41 (+1.37%) ▲|PG165.05+8.21 (+5.23%) ▲|PLTR201.64-0.08 (-0.04%) ▼|PM199.56+2.10 (+1.06%) ▲|QCOM177.27-0.70 (-0.39%) ▼|RTX192.52+0.92 (+0.48%) ▲|SBUX100.73+1.65 (+1.67%) ▲|SCHW92.04+0.40 (+0.44%) ▲|SO92.03+1.64 (+1.81%) ▲|SPG209.18+3.63 (+1.76%) ▲|T22.60+0.69 (+3.15%) ▲|TMO683.90-10.12 (-1.46%) ▼|TMUS158.02+4.27 (+2.78%) ▲|TSLA387.00+0.53 (+0.14%) ▲|TXN283.52-1.13 (-0.40%) ▼|UBER68.50+0.88 (+1.29%) ▲|UNH422.09+5.09 (+1.22%) ▲|UNP294.15+6.28 (+2.18%) ▲|UPS100.98+1.41 (+1.42%) ▲|USB59.68+0.63 (+1.06%) ▲|V410.99+3.14 (+0.77%) ▲|VZ44.82+1.26 (+2.88%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT118.77+0.97 (+0.82%) ▲|XOM176.60-1.49 (-0.84%) ▼|AAPL345.41+1.42 (+0.41%) ▲|ABBV282.81-1.91 (-0.67%) ▼|ABT100.83+0.32 (+0.32%) ▲|ACN243.65+3.39 (+1.41%) ▲|ADBE261.00+5.94 (+2.33%) ▲|AMAT385.01-23.93 (-5.85%) ▼|AMD520.57-32.15 (-5.82%) ▼|AMGN447.10+8.76 (+2.00%) ▲|AMT181.05+3.41 (+1.92%) ▲|AMZN253.55-8.83 (-3.36%) ▼|AVGO328.88-8.92 (-2.64%) ▼|AXP325.91+2.30 (+0.71%) ▲|BA190.70-1.58 (-0.82%) ▼|BAC51.04+0.26 (+0.51%) ▲|BKNG164.56+6.18 (+3.90%) ▲|BLK1,152.99+3.39 (+0.29%) ▲|BMY62.13+1.01 (+1.65%) ▲|BNY144.81-1.05 (-0.72%) ▼|BRK-B545.07+6.08 (+1.13%) ▲|C123.17-0.68 (-0.55%) ▼|CAT710.58-29.63 (-4.00%) ▼|CL96.06+2.66 (+2.85%) ▲|CMCSA23.08+1.00 (+4.51%) ▲|COF208.00+1.34 (+0.65%) ▲|COP144.42-1.26 (-0.86%) ▼|COST1,005.53+7.22 (+0.72%) ▲|CRM245.89+4.11 (+1.70%) ▲|CSCO104.85-2.41 (-2.25%) ▼|CVS93.47+0.69 (+0.74%) ▲|CVX225.32-1.47 (-0.65%) ▼|DE632.04-4.50 (-0.71%) ▼|DHR233.42-0.45 (-0.19%) ▼|DIS112.53+0.70 (+0.63%) ▲|DUK122.53+1.86 (+1.54%) ▲|EMR157.73-5.38 (-3.30%) ▼|FDX302.19+3.96 (+1.33%) ▲|GD346.65+1.94 (+0.56%) ▲|GE290.96-4.92 (-1.66%) ▼|GEV849.17-76.75 (-8.29%) ▼|GILD156.14+2.57 (+1.67%) ▲|GM77.98+1.87 (+2.46%) ▲|GOOG323.80-7.15 (-2.16%) ▼|GOOGL327.81-6.95 (-2.08%) ▼|GS899.02-5.71 (-0.63%) ▼|HD322.34+8.20 (+2.61%) ▲|HON213.10-1.64 (-0.76%) ▼|IBM243.58-7.88 (-3.13%) ▼|INTC88.10-4.86 (-5.23%) ▼|INTU347.07+11.46 (+3.41%) ▲|ISRG436.70+8.58 (+2.00%) ▲|JNJ263.16+5.38 (+2.09%) ▲|JPM335.97+0.78 (+0.23%) ▲|KO94.12+1.44 (+1.55%) ▲|LIN504.02+3.45 (+0.69%) ▲|LLY1,305.45+34.70 (+2.73%) ▲|LMT587.36+35.85 (+6.50%) ▲|LOW201.93+5.37 (+2.73%) ▲|LRCX238.04-22.77 (-8.73%) ▼|MA627.22+4.60 (+0.74%) ▲|MCD249.03+2.78 (+1.13%) ▲|MDLZ63.83+1.09 (+1.74%) ▲|MDT94.57+1.54 (+1.66%) ▲|META655.19-42.33 (-6.07%) ▼|MMM175.45+0.71 (+0.40%) ▲|MO74.82+0.99 (+1.34%) ▲|MRK153.13+3.25 (+2.17%) ▲|MS185.19-1.82 (-0.97%) ▼|MSFT524.76-8.20 (-1.54%) ▼|MU897.15-16.52 (-1.81%) ▼|NEE80.42+2.14 (+2.73%) ▲|NFLX66.40+1.36 (+2.09%) ▲|NKE37.75+0.22 (+0.57%) ▲|NOW155.48+2.36 (+1.54%) ▲|NVDA215.93-6.04 (-2.72%) ▼|ORCL127.11-2.03 (-1.57%) ▼|PEP136.89+2.19 (+1.63%) ▲|PFE30.26+0.41 (+1.37%) ▲|PG165.05+8.21 (+5.23%) ▲|PLTR201.64-0.08 (-0.04%) ▼|PM199.56+2.10 (+1.06%) ▲|QCOM177.27-0.70 (-0.39%) ▼|RTX192.52+0.92 (+0.48%) ▲|SBUX100.73+1.65 (+1.67%) ▲|SCHW92.04+0.40 (+0.44%) ▲|SO92.03+1.64 (+1.81%) ▲|SPG209.18+3.63 (+1.76%) ▲|T22.60+0.69 (+3.15%) ▲|TMO683.90-10.12 (-1.46%) ▼|TMUS158.02+4.27 (+2.78%) ▲|TSLA387.00+0.53 (+0.14%) ▲|TXN283.52-1.13 (-0.40%) ▼|UBER68.50+0.88 (+1.29%) ▲|UNH422.09+5.09 (+1.22%) ▲|UNP294.15+6.28 (+2.18%) ▲|UPS100.98+1.41 (+1.42%) ▲|USB59.68+0.63 (+1.06%) ▲|V410.99+3.14 (+0.77%) ▲|VZ44.82+1.26 (+2.88%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT118.77+0.97 (+0.82%) ▲|XOM176.60-1.49 (-0.84%) ▼|
10.4 C
New York
Thursday, October 22, 2026

Tag: treatment

Piston Bio Receives Endorsement from Leading Oncologists for its Tumor Antigen-Inducing Therapeutic

MORRISTOWN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Piston Bio LLC, a biotechnology company developing both small molecules and biologics for the treatment of cancer, today announced that its scientific advisors have endorsed the potential of its next-generation therapeutic designed to induce tumor surface antigens and prevent immune escape. The endorsement follows a scientific advisory board meeting convened last month to review nonclinical data.

Momar Named Among the Best Companies to Sell For in the United States

Momar is included in Selling Power's List of 60 Best Companies to Sell For in 2025 ATLANTA, July 15, 2025 /PRNewswire/ -- Momar earned its...

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius...

Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition of the SmarTest® Patch to its portfolio of non-invasive drug testing solutions. The SmarTest Patch is an innovative wearable device, developed by SMARTOX®, that enables continuous drug detection through sweat over a 7 to 10-day period. The SmarTest Patch complements the Company's flagship product, the Intelligent Fingerprinting Drug Testing Solution, strengthening its product portfolio of sweat-based, non-invasive testing technologies.

Water First Launches New Internship in Collaboration with Seven First Nations Communities in Southern Ontario

Nonprofit launches new internship program to train 10 Indigenous adults from across Southern Ontario to become certified water operators

Youthful Narrative Bridges Traditional Chinese Medicine to Global Audience

LIAOCHENG, China, July 15, 2025 /PRNewswire/ -- Amidst global challenges in chronic disease prevention and health management, Traditional Chinese Medicine (TCM)'s core principles of...

Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors

Cardiff, United Kingdom – 15 July 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today announces the appointment of Douglas E. Williams, Ph.D. as independent Chair of its Board of Directors. He takes over from Ruth McKernan, who retains her role on the Board as a Director and Interim Chief Executive Officer (CEO).

AXA and China Biotech Services Sign Memorandum of Understanding

Joint effort to explore innovative cancer treatment solutions and broaden options for customers HONG KONG, July 15, 2025 /PRNewswire/ -- AXA China Region Insurance Company...

Topflight Pharma Development Veteran Joins Synendos

Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy.

Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026.

Divamics’ AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners

SUZHOU, China, July 15, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through...

Divamics’ AI and Molecular Dynamics Platform Powers Breakthroughs in Metabolic Disease Drug Discovery for Partners

SUZHOU, China, July 14, 2025 /PRNewswire/ -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through...

Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the...

-          The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatment